| NCT ID | NCT06258109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Cervical Artery Dissection |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-01-01 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data. Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers. Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.
Eligibility Criteria
Inclusion Criteria: * female * prior symptomatic cervical artery dissection (= index CeAD) * at least one long-term follow-up visit (at least 6 months after the initial event) * with information available on outcome events: * recurrent dissection * ischemic stroke * hemorrhagic stroke * functional outcome assessed by mRS score * with data on pregnancy after the initial event * at least 18 years old at the initial event Exclusion Criteria: * Male patients * Age \<18 years * No long-term follow-up available or long-term follow-up \< 6 months after initial event * No data on pregnancy after initial event available
Contact & Investigator
Stefan T Engelter, MD
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06258109 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervical Artery Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06258109 currently recruiting?
Yes, NCT06258109 is actively recruiting participants. Contact the research team at stefan.engelter@felixplatter.ch for enrollment information.
Where is the NCT06258109 trial being conducted?
This trial is being conducted at Salt Lake City, United States, Charlottesville, United States, Córdoba, Argentina, Innsbruck, Austria and 8 additional locations.
Who is sponsoring the NCT06258109 clinical trial?
NCT06258109 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Stefan T Engelter, MD at University Hospital, Basel, Switzerland. The trial plans to enroll 1,000 participants.